Paper Info
Title
AI-Driven Synthetic Biology for Non-Small Cell Lung Cancer Drug Effectiveness-Cost Analysis in Intelligent Assisted Medical Systems
Abstract
According to statistics, in the 185 countries' 36 types of cancer, the morbidity and mortality of lung cancer take the first place, and non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer (International Agency for Research on Cancer, 2018), (Bray <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">et al.</i> , 2018). Significantly in many developing countries, limited medical resources and excess population seriously affect the diagnosis and treatment of alung cancer patients. The 21st century is an era of life medicine, big data, and information technology. Synthetic biology is known as the driving force of natural product innovation and research in this era. Based on the research of NSCLC targeted drugs, through the cross-fusion of synthetic biology and artificial intelligence, using the idea of bioengineering, we construct an artificial intelligence assisted medical system and propose a drug selection framework for the personalized selection of NSCLC patients. Under the premise of ensuring the efficacy, considering the economic cost of targeted drugs as an auxiliary decision-making factor, the system predicts the drug effectiveness-cost then. The experiment shows that our method can rely on the provided clinical data to screen drug treatment programs suitable for the patient's conditions and assist doctors in making an efficient diagnosis.
Year
DOI
Venue
2022
10.1109/JBHI.2021.3133455
IEEE Journal of Biomedical and Health Informatics
Keywords
DocType
Volume
Non-small cell lung cancer (NSCLC),targeted drug therapy,synthetic biology,artificial intelligence medical system,drug effectiveness-cost analysis
Journal
26
Issue
ISSN
Citations 
10
2168-2194
0
PageRank 
References 
Authors
0.34
0
5
Name
Order
Citations
PageRank
Chang Liu1571117.41
Jia Wu200.34
Nour Moustafa300.34
Ali Kashif Bashir442.41
Keping Yu500.34